Skip to main content

Table 1 Baseline characteristics of patients in the training, internal validation, and external validation cohorts

From: Computer-assisted quantification of tumor-associated collagen signatures to improve the prognosis prediction of breast cancer

Characteristics Fuzhou training cohort (355) Fuzhou internal validation cohort (334) Harbin external validation cohort (253) Total cohort (942)
Age
 ≤50 199 (56.1%) 194 (58.1%) 136 (53.8%) 529 (56.2%)
 >50 156 (43.9%) 140 (41.9%) 117 (46.2%) 413 (43.8%)
Molecular subtype
 Luminal A 75 (21.1%) 59 (17.7%) 69 (27.3%) 203 (21.5%)
 Luminal B 161 (45.4%) 145 (43.4%) 97 (38.3%) 403 (42.8%)
 HER2-enriched 64 (18.0%) 75 (22.5%) 48 (19.0%) 187 (19.9%)
 Triple negative 55 (15.5%) 55 (16.5%) 39 (15.4%) 149 (15.8%)
Tumor size
 ≤2cm 147 (41.4%) 134 (40.1%) 143 (56.5%) 424 (45.0%)
 2–5cm 187 (52.7%) 174 (52.1%) 107 (42.3%) 468 (49.7%)
 >5cm 21 (5.9%) 26 (7.8%) 3 (1.2%) 50 (5.3%)
Nodal status
 0 180 (50.7%) 169 (50.6%) 117 (46.3%) 466 (49.5%)
 1–3 74 (20.8%) 81 (24.3%) 75 (29.6%) 230 (24.4%)
 ≥4 101 (28.5%) 84 (25.1%) 61 (24.1%) 246 (26.1%)
Clinical stage
 I 96 (27.0%) 83 (24.9%) 74 (29.3%) 253 (26.9%)
 II 156 (43.9%) 161 (48.2%) 117 (46.2%) 434 (46.1%)
 III 103 (29.1%) 90 (26.9%) 62 (24.5%) 255 (27.0%)
Histological grade
 G1 56 (15.8%) 56 (16.8%) 11 (4.4%) 123 (13.1%)
 G2 194 (54.6%) 176 (52.7%) 202 (79.8%) 572 (60.7%)
 G3 105 (29.6%) 102 (30.5%) 40 (15.8%) 247 (26.2%)
ER
 Negative 119 (33.5%) 130 (38.9%) 87 (34.4%) 336 (35.7%)
 Positive 236 (66.5%) 204 (61.1%) 166 (65.6%) 606 (64.3%)
PR
 Negative 152 (42.8%) 155 (46.4%) 108 (42.7%) 415 (44.1%)
 Positive 203 (57.2%) 179 (53.6%) 145 (57.3%) 527 (55.9%)
HER2
 Negative 243 (68.5%) 213 (63.8%) 171 (67.6%) 627 (66.6%)
 Positive 112 (31.5%) 121 (36.2%) 82 (32.4%) 315 (33.4%)
Chemotherapy
 No 28 (7.9%) 28 (8.4%) 27 (10.7%) 83 (8.8%)
 Yes 327 (92.1%) 306 (91.6%) 226 (89.3%) 859 (91.2%)
Endocrine therapy
 No 135 (38.0%) 140 (41.9%) 133 (52.6%) 408 (43.3%)
 Yes 220 (62.0%) 194 (58.1%) 120 (47.4%) 534 (56.7%)
Radiation therapy
 No 234 (65.9%) 232 (69.5%) 195 (77.1%) 661 (70.2%)
 Yes 121 (34.1%) 102 (30.5%) 58 (22.9%) 281 (29.8%)
Targeted therapy
 No 331 (93.2%) 311 (93.1%) 228 (90.1%) 870 (92.4%)
 Yes 24 (6.8%) 23 (6.9%) 25 (9.9%) 72 (7.6%)
  1. Note: ER, estrogen receptor; PR, progesterone receptor